nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrimethamine—CYP2C8—Paclitaxel—ovarian cancer	0.119	0.339	CbGbCtD
Pyrimethamine—CYP2D6—Vinorelbine—ovarian cancer	0.108	0.308	CbGbCtD
Pyrimethamine—CYP2C9—Paclitaxel—ovarian cancer	0.0831	0.237	CbGbCtD
Pyrimethamine—CYP2D6—Doxorubicin—ovarian cancer	0.0409	0.117	CbGbCtD
Pyrimethamine—DHFR—Nucleotide Metabolism—NME2—ovarian cancer	0.0309	0.12	CbGpPWpGaD
Pyrimethamine—Pancytopenia—Altretamine—ovarian cancer	0.0183	0.0672	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—FOLR1—ovarian cancer	0.014	0.0542	CbGpPWpGaD
Pyrimethamine—Leukopenia—Altretamine—ovarian cancer	0.012	0.0442	CcSEcCtD
Pyrimethamine—DHFR—myometrium—ovarian cancer	0.0109	0.0961	CbGeAlD
Pyrimethamine—Thrombocytopenia—Altretamine—ovarian cancer	0.0107	0.0394	CcSEcCtD
Pyrimethamine—DHFR—embryo—ovarian cancer	0.0105	0.0924	CbGeAlD
Pyrimethamine—Anorexia—Altretamine—ovarian cancer	0.0104	0.0384	CcSEcCtD
Pyrimethamine—Decreased appetite—Altretamine—ovarian cancer	0.00952	0.035	CcSEcCtD
Pyrimethamine—DHFR—uterine cervix—ovarian cancer	0.00849	0.0748	CbGeAlD
Pyrimethamine—DHFR—decidua—ovarian cancer	0.00809	0.0713	CbGeAlD
Pyrimethamine—DHFR—G1/S-Specific Transcription—CCNE1—ovarian cancer	0.00779	0.0302	CbGpPWpGaD
Pyrimethamine—DHFR—endometrium—ovarian cancer	0.00768	0.0676	CbGeAlD
Pyrimethamine—DHFR—G1/S-Specific Transcription—TYMS—ovarian cancer	0.00765	0.0297	CbGpPWpGaD
Pyrimethamine—Toxic epidermal necrolysis—Chlorambucil—ovarian cancer	0.00713	0.0262	CcSEcCtD
Pyrimethamine—DHFR—gonad—ovarian cancer	0.00713	0.0627	CbGeAlD
Pyrimethamine—DHFR—uterus—ovarian cancer	0.00708	0.0623	CbGeAlD
Pyrimethamine—Vomiting—Altretamine—ovarian cancer	0.00697	0.0256	CcSEcCtD
Pyrimethamine—Pancytopenia—Chlorambucil—ovarian cancer	0.0065	0.0239	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00644	0.025	CbGpPWpGaD
Pyrimethamine—DHFR—female reproductive system—ovarian cancer	0.00636	0.056	CbGeAlD
Pyrimethamine—Stevens-Johnson syndrome—Chlorambucil—ovarian cancer	0.00605	0.0222	CcSEcCtD
Pyrimethamine—DHFR—bone marrow—ovarian cancer	0.00601	0.0529	CbGeAlD
Pyrimethamine—DHFR—female gonad—ovarian cancer	0.00579	0.051	CbGeAlD
Pyrimethamine—Pancytopenia—Topotecan—ovarian cancer	0.00579	0.0213	CcSEcCtD
Pyrimethamine—DHFR—vagina—ovarian cancer	0.00576	0.0507	CbGeAlD
Pyrimethamine—Pancytopenia—Melphalan—ovarian cancer	0.00567	0.0208	CcSEcCtD
Pyrimethamine—DHFR—Metabolism of nitric oxide—CAV1—ovarian cancer	0.00564	0.0219	CbGpPWpGaD
Pyrimethamine—DHFR—E2F transcription factor network—RBL2—ovarian cancer	0.00544	0.0211	CbGpPWpGaD
Pyrimethamine—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00534	0.0207	CbGpPWpGaD
Pyrimethamine—Lamotrigine—ABCB1—ovarian cancer	0.00534	1	CrCbGaD
Pyrimethamine—Erythema multiforme—Chlorambucil—ovarian cancer	0.00518	0.019	CcSEcCtD
Pyrimethamine—DHFR—testis—ovarian cancer	0.00514	0.0452	CbGeAlD
Pyrimethamine—DHFR—One Carbon Metabolism—TYMS—ovarian cancer	0.00513	0.0199	CbGpPWpGaD
Pyrimethamine—Pancytopenia—Vinorelbine—ovarian cancer	0.00495	0.0182	CcSEcCtD
Pyrimethamine—DHFR—E2F mediated regulation of DNA replication—PPP2R1A—ovarian cancer	0.00494	0.0191	CbGpPWpGaD
Pyrimethamine—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00486	0.0189	CbGpPWpGaD
Pyrimethamine—DHFR—Trans-sulfuration and one carbon metabolism—TYMS—ovarian cancer	0.00461	0.0179	CbGpPWpGaD
Pyrimethamine—DHFR—E2F mediated regulation of DNA replication—CCNE1—ovarian cancer	0.00458	0.0178	CbGpPWpGaD
Pyrimethamine—DHFR—Fluoropyrimidine Activity—TYMS—ovarian cancer	0.0045	0.0175	CbGpPWpGaD
Pyrimethamine—DHFR—E2F mediated regulation of DNA replication—TYMS—ovarian cancer	0.0045	0.0175	CbGpPWpGaD
Pyrimethamine—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00435	0.0169	CbGpPWpGaD
Pyrimethamine—Leukopenia—Chlorambucil—ovarian cancer	0.00427	0.0157	CcSEcCtD
Pyrimethamine—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00396	0.0153	CbGpPWpGaD
Pyrimethamine—CYP2C8—endometrium—ovarian cancer	0.00381	0.0336	CbGeAlD
Pyrimethamine—Thrombocytopenia—Chlorambucil—ovarian cancer	0.00381	0.014	CcSEcCtD
Pyrimethamine—Leukopenia—Topotecan—ovarian cancer	0.0038	0.014	CcSEcCtD
Pyrimethamine—DHFR—lymph node—ovarian cancer	0.00372	0.0328	CbGeAlD
Pyrimethamine—Leukopenia—Melphalan—ovarian cancer	0.00372	0.0137	CcSEcCtD
Pyrimethamine—Anorexia—Chlorambucil—ovarian cancer	0.00371	0.0136	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Paclitaxel—ovarian cancer	0.00365	0.0134	CcSEcCtD
Pyrimethamine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.00361	0.014	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Topotecan—ovarian cancer	0.00347	0.0127	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Melphalan—ovarian cancer	0.00339	0.0125	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Topotecan—ovarian cancer	0.00339	0.0125	CcSEcCtD
Pyrimethamine—Decreased appetite—Chlorambucil—ovarian cancer	0.00338	0.0124	CcSEcCtD
Pyrimethamine—Pancytopenia—Paclitaxel—ovarian cancer	0.00333	0.0122	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—RBL2—ovarian cancer	0.00332	0.0129	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Melphalan—ovarian cancer	0.00332	0.0122	CcSEcCtD
Pyrimethamine—Anorexia—Topotecan—ovarian cancer	0.0033	0.0121	CcSEcCtD
Pyrimethamine—Leukopenia—Vinorelbine—ovarian cancer	0.00325	0.012	CcSEcCtD
Pyrimethamine—Anorexia—Melphalan—ovarian cancer	0.00324	0.0119	CcSEcCtD
Pyrimethamine—CYP2C8—female reproductive system—ovarian cancer	0.00316	0.0278	CbGeAlD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.00314	0.0122	CbGpPWpGaD
Pyrimethamine—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.0031	0.0114	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.0031	0.0114	CcSEcCtD
Pyrimethamine—Decreased appetite—Topotecan—ovarian cancer	0.00301	0.0111	CcSEcCtD
Pyrimethamine—Haematuria—Paclitaxel—ovarian cancer	0.00298	0.011	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00297	0.0109	CcSEcCtD
Pyrimethamine—Decreased appetite—Melphalan—ovarian cancer	0.00295	0.0108	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.0029	0.0107	CcSEcCtD
Pyrimethamine—Hypersensitivity—Chlorambucil—ovarian cancer	0.00287	0.0105	CcSEcCtD
Pyrimethamine—CYP2C8—vagina—ovarian cancer	0.00286	0.0252	CbGeAlD
Pyrimethamine—DHFR—Folate Metabolism—SOD1—ovarian cancer	0.00285	0.011	CbGpPWpGaD
Pyrimethamine—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—ovarian cancer	0.00283	0.011	CbGpPWpGaD
Pyrimethamine—Anorexia—Vinorelbine—ovarian cancer	0.00283	0.0104	CcSEcCtD
Pyrimethamine—Pancytopenia—Docetaxel—ovarian cancer	0.00282	0.0104	CcSEcCtD
Pyrimethamine—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—FASN—ovarian cancer	0.00281	0.0109	CbGpPWpGaD
Pyrimethamine—CYP2C9—female reproductive system—ovarian cancer	0.00281	0.0247	CbGeAlD
Pyrimethamine—DHFR—E2F transcription factor network—BRCA1—ovarian cancer	0.00277	0.0108	CbGpPWpGaD
Pyrimethamine—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—ovarian cancer	0.00267	0.0104	CbGpPWpGaD
Pyrimethamine—Erythema multiforme—Paclitaxel—ovarian cancer	0.00265	0.00975	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.00263	0.00966	CcSEcCtD
Pyrimethamine—DHFR—G1/S Transition—SKP2—ovarian cancer	0.00263	0.0102	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—RSF1—ovarian cancer	0.00259	0.01	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Vinorelbine—ovarian cancer	0.00258	0.00947	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—SOD2—ovarian cancer	0.00257	0.00995	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Topotecan—ovarian cancer	0.00255	0.00939	CcSEcCtD
Pyrimethamine—CYP2C8—testis—ovarian cancer	0.00255	0.0225	CbGeAlD
Pyrimethamine—Hypersensitivity—Melphalan—ovarian cancer	0.0025	0.00919	CcSEcCtD
Pyrimethamine—Vomiting—Chlorambucil—ovarian cancer	0.00248	0.0091	CcSEcCtD
Pyrimethamine—CYP2C8—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.00247	0.00957	CbGpPWpGaD
Pyrimethamine—DHFR—E2F transcription factor network—CCNE1—ovarian cancer	0.00243	0.00942	CbGpPWpGaD
Pyrimethamine—DHFR—E2F transcription factor network—TYMS—ovarian cancer	0.00239	0.00925	CbGpPWpGaD
Pyrimethamine—Erythema multiforme—Docetaxel—ovarian cancer	0.00225	0.00827	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—SKP2—ovarian cancer	0.00221	0.00858	CbGpPWpGaD
Pyrimethamine—Vomiting—Topotecan—ovarian cancer	0.0022	0.0081	CcSEcCtD
Pyrimethamine—Leukopenia—Paclitaxel—ovarian cancer	0.00219	0.00804	CcSEcCtD
Pyrimethamine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00218	0.00803	CcSEcCtD
Pyrimethamine—Vomiting—Melphalan—ovarian cancer	0.00216	0.00793	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.00211	0.00818	CbGpPWpGaD
Pyrimethamine—CYP2D6—female reproductive system—ovarian cancer	0.00211	0.0185	CbGeAlD
Pyrimethamine—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.00209	0.00768	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.00207	0.00804	CbGpPWpGaD
Pyrimethamine—CYP2D6—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.00203	0.00786	CbGpPWpGaD
Pyrimethamine—CYP2C9—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.00201	0.00779	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00199	0.00733	CcSEcCtD
Pyrimethamine—DHFR—Metabolism of nitric oxide—AKT1—ovarian cancer	0.00196	0.0076	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00195	0.00718	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.00193	0.0071	CcSEcCtD
Pyrimethamine—CYP2D6—female gonad—ovarian cancer	0.00192	0.0169	CbGeAlD
Pyrimethamine—Pancytopenia—Epirubicin—ovarian cancer	0.0019	0.007	CcSEcCtD
Pyrimethamine—Anorexia—Paclitaxel—ovarian cancer	0.0019	0.00699	CcSEcCtD
Pyrimethamine—DHFR—G1/S Transition—PPP2R1A—ovarian cancer	0.0019	0.00736	CbGpPWpGaD
Pyrimethamine—Vomiting—Vinorelbine—ovarian cancer	0.00189	0.00693	CcSEcCtD
Pyrimethamine—Leukopenia—Docetaxel—ovarian cancer	0.00185	0.00681	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00177	0.00651	CcSEcCtD
Pyrimethamine—DHFR—G1/S Transition—CCNE1—ovarian cancer	0.00176	0.00683	CbGpPWpGaD
Pyrimethamine—Pancytopenia—Doxorubicin—ovarian cancer	0.00176	0.00648	CcSEcCtD
Pyrimethamine—Decreased appetite—Paclitaxel—ovarian cancer	0.00173	0.00637	CcSEcCtD
Pyrimethamine—DHFR—G1/S Transition—TYMS—ovarian cancer	0.00173	0.00671	CbGpPWpGaD
Pyrimethamine—Haematuria—Epirubicin—ovarian cancer	0.0017	0.00626	CcSEcCtD
Pyrimethamine—CYP2D6—testis—ovarian cancer	0.0017	0.015	CbGeAlD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—CCND2—ovarian cancer	0.0017	0.00657	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Docetaxel—ovarian cancer	0.00169	0.00621	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Docetaxel—ovarian cancer	0.00166	0.00608	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.00164	0.00603	CcSEcCtD
Pyrimethamine—Anorexia—Docetaxel—ovarian cancer	0.00161	0.00592	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—PPP2R1A—ovarian cancer	0.0016	0.0062	CbGpPWpGaD
Pyrimethamine—Haematuria—Doxorubicin—ovarian cancer	0.00158	0.0058	CcSEcCtD
Pyrimethamine—CYP2D6—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.00157	0.00607	CbGpPWpGaD
Pyrimethamine—Erythema multiforme—Epirubicin—ovarian cancer	0.00152	0.00558	CcSEcCtD
Pyrimethamine—DHFR—Fluoropyrimidine Activity—TP53—ovarian cancer	0.00149	0.00579	CbGpPWpGaD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—CCNE1—ovarian cancer	0.00148	0.00576	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Docetaxel—ovarian cancer	0.00147	0.0054	CcSEcCtD
Pyrimethamine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00147	0.0054	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—TYMS—ovarian cancer	0.00146	0.00565	CbGpPWpGaD
Pyrimethamine—Erythema multiforme—Doxorubicin—ovarian cancer	0.0014	0.00516	CcSEcCtD
Pyrimethamine—DHFR—Cell Cycle—RAD51C—ovarian cancer	0.00136	0.00527	CbGpPWpGaD
Pyrimethamine—DHFR—Folate Metabolism—IL2—ovarian cancer	0.00134	0.00518	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.00133	0.00515	CbGpPWpGaD
Pyrimethamine—Vomiting—Paclitaxel—ovarian cancer	0.00127	0.00466	CcSEcCtD
Pyrimethamine—DHFR—E2F transcription factor network—CDKN1B—ovarian cancer	0.00126	0.00488	CbGpPWpGaD
Pyrimethamine—Leukopenia—Epirubicin—ovarian cancer	0.00125	0.0046	CcSEcCtD
Pyrimethamine—Hypersensitivity—Docetaxel—ovarian cancer	0.00125	0.00458	CcSEcCtD
Pyrimethamine—CYP2C8—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.00123	0.00478	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.00122	0.00473	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—PPP1CC—ovarian cancer	0.00119	0.0046	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—HSD17B6—ovarian cancer	0.00118	0.00459	CbGpPWpGaD
Pyrimethamine—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.00118	0.00458	CbGpPWpGaD
Pyrimethamine—Leukopenia—Doxorubicin—ovarian cancer	0.00116	0.00425	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Epirubicin—ovarian cancer	0.00114	0.00419	CcSEcCtD
Pyrimethamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.00113	0.00436	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Epirubicin—ovarian cancer	0.00112	0.0041	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.00109	0.00424	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—RBL2—ovarian cancer	0.00109	0.00423	CbGpPWpGaD
Pyrimethamine—Anorexia—Epirubicin—ovarian cancer	0.00109	0.00399	CcSEcCtD
Pyrimethamine—Vomiting—Docetaxel—ovarian cancer	0.00107	0.00395	CcSEcCtD
Pyrimethamine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.00107	0.00413	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.00105	0.00388	CcSEcCtD
Pyrimethamine—CYP2C8—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.00105	0.00408	CbGpPWpGaD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.00104	0.00405	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.00103	0.0038	CcSEcCtD
Pyrimethamine—Anorexia—Doxorubicin—ovarian cancer	0.00101	0.0037	CcSEcCtD
Pyrimethamine—CYP2C9—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.001	0.00389	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Epirubicin—ovarian cancer	0.000991	0.00364	CcSEcCtD
Pyrimethamine—DHFR—E2F transcription factor network—MYC—ovarian cancer	0.000963	0.00373	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CHMP4C—ovarian cancer	0.000945	0.00367	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Doxorubicin—ovarian cancer	0.000917	0.00337	CcSEcCtD
Pyrimethamine—DHFR—G1/S Transition—CDKN1B—ovarian cancer	0.000913	0.00354	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—NME2—ovarian cancer	0.000906	0.00351	CbGpPWpGaD
Pyrimethamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000875	0.00339	CbGpPWpGaD
Pyrimethamine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000868	0.00336	CbGpPWpGaD
Pyrimethamine—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000864	0.00335	CbGpPWpGaD
Pyrimethamine—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000864	0.00335	CbGpPWpGaD
Pyrimethamine—DHFR—Folate Metabolism—TP53—ovarian cancer	0.000857	0.00332	CbGpPWpGaD
Pyrimethamine—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000856	0.00332	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Epirubicin—ovarian cancer	0.00084	0.00309	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000837	0.00325	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—BCL9—ovarian cancer	0.00082	0.00318	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000811	0.00315	CbGpPWpGaD
Pyrimethamine—DHFR—Folate Metabolism—IL6—ovarian cancer	0.000785	0.00304	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000777	0.00286	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.00077	0.00298	CbGpPWpGaD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.000734	0.00285	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—MLH1—ovarian cancer	0.000734	0.00284	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—SKP2—ovarian cancer	0.000725	0.00281	CbGpPWpGaD
Pyrimethamine—Vomiting—Epirubicin—ovarian cancer	0.000725	0.00266	CcSEcCtD
Pyrimethamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.00071	0.00275	CbGpPWpGaD
Pyrimethamine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000703	0.00273	CbGpPWpGaD
Pyrimethamine—DHFR—G1/S Transition—MYC—ovarian cancer	0.000699	0.00271	CbGpPWpGaD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000687	0.00267	CbGpPWpGaD
Pyrimethamine—Vomiting—Doxorubicin—ovarian cancer	0.000671	0.00247	CcSEcCtD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.000622	0.00241	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—PPP1CC—ovarian cancer	0.000609	0.00236	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CHEK2—ovarian cancer	0.000593	0.0023	CbGpPWpGaD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—MYC—ovarian cancer	0.000589	0.00228	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.000587	0.00227	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—CYTB—ovarian cancer	0.000584	0.00226	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CCND2—ovarian cancer	0.000556	0.00216	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—BRCA1—ovarian cancer	0.000556	0.00216	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—CCNE1—ovarian cancer	0.000545	0.00211	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—TYMS—ovarian cancer	0.000535	0.00207	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—PPP2R1A—ovarian cancer	0.000524	0.00203	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PPP1CC—ovarian cancer	0.00051	0.00198	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—BRIP1—ovarian cancer	0.00051	0.00198	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—BRCA2—ovarian cancer	0.000503	0.00195	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CCNE1—ovarian cancer	0.000487	0.00189	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—BIRC5—ovarian cancer	0.000481	0.00187	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—TYMS—ovarian cancer	0.000478	0.00185	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—HDAC6—ovarian cancer	0.000462	0.00179	CbGpPWpGaD
Pyrimethamine—CYP2C8—Biological oxidations—CYP1B1—ovarian cancer	0.000459	0.00178	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000453	0.00176	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—BIRC5—ovarian cancer	0.00043	0.00167	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—TERT—ovarian cancer	0.000417	0.00162	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—XIAP—ovarian cancer	0.0004	0.00155	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—SMARCA4—ovarian cancer	0.00039	0.00151	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—EREG—ovarian cancer	0.000381	0.00148	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	0.000377	0.00146	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	0.000374	0.00145	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000372	0.00144	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000369	0.00143	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000354	0.00137	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—YAP1—ovarian cancer	0.000342	0.00133	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—FASN—ovarian cancer	0.000333	0.00129	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—PARP1—ovarian cancer	0.000332	0.00129	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—SLC2A1—ovarian cancer	0.000316	0.00123	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000288	0.00112	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	0.000282	0.00109	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—NME2—ovarian cancer	0.00028	0.00109	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—FASN—ovarian cancer	0.000279	0.00108	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—SLC5A5—ovarian cancer	0.000274	0.00106	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—CCND1—ovarian cancer	0.000269	0.00104	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—PPP2R1A—ovarian cancer	0.000269	0.00104	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—SLC2A1—ovarian cancer	0.000265	0.00103	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—CYP1B1—ovarian cancer	0.000254	0.000985	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CDKN1B—ovarian cancer	0.000252	0.000979	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CCND1—ovarian cancer	0.000241	0.000934	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000237	0.000921	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—NME2—ovarian cancer	0.00023	0.000891	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—NME2—ovarian cancer	0.000228	0.000883	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PPP2R1A—ovarian cancer	0.000225	0.000874	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—MAPK3—ovarian cancer	0.000222	0.000861	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—MYC—ovarian cancer	0.000216	0.000838	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—TERT—ovarian cancer	0.000214	0.000829	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—MAPK1—ovarian cancer	0.000211	0.000819	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—ABCB1—ovarian cancer	0.000209	0.000811	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—TYMS—ovarian cancer	0.000205	0.000797	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—MAPK3—ovarian cancer	0.000199	0.00077	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CAV1—ovarian cancer	0.000198	0.000767	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000194	0.000751	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000193	0.000749	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—MYC—ovarian cancer	0.000193	0.000749	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—MAPK1—ovarian cancer	0.000189	0.000733	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—IL6ST—ovarian cancer	0.000187	0.000727	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CYTB—ovarian cancer	0.00018	0.000699	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—APC—ovarian cancer	0.00018	0.000698	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000176	0.000684	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—CAV1—ovarian cancer	0.000166	0.000642	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—TP53—ovarian cancer	0.000159	0.000615	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—PIK3CD—ovarian cancer	0.000158	0.000614	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PPP1CC—ovarian cancer	0.000158	0.000611	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—BRIP1—ovarian cancer	0.000158	0.000611	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000158	0.000611	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PIK3CG—ovarian cancer	0.000151	0.000585	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CYTB—ovarian cancer	0.000148	0.000574	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CYTB—ovarian cancer	0.000147	0.000569	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000143	0.000556	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—ERBB2—ovarian cancer	0.00014	0.000542	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—MTOR—ovarian cancer	0.000138	0.000535	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—PIK3CB—ovarian cancer	0.000138	0.000535	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PIK3CD—ovarian cancer	0.000133	0.000514	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CDKN1B—ovarian cancer	0.000129	0.000502	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PPP1CC—ovarian cancer	0.000129	0.000502	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—BRIP1—ovarian cancer	0.000129	0.000502	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PPP1CC—ovarian cancer	0.000128	0.000498	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—BRIP1—ovarian cancer	0.000128	0.000498	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CTNNB1—ovarian cancer	0.000122	0.000474	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—PTEN—ovarian cancer	0.000119	0.000462	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PIK3CB—ovarian cancer	0.000116	0.000448	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	0.000115	0.000445	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—STAT3—ovarian cancer	0.000107	0.000413	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—NRAS—ovarian cancer	0.000106	0.000412	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—YAP1—ovarian cancer	0.000106	0.00041	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	0.000105	0.000406	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—MAPK3—ovarian cancer	0.000102	0.000395	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PTEN—ovarian cancer	9.99e-05	0.000387	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—MYC—ovarian cancer	9.91e-05	0.000384	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—MAPK1—ovarian cancer	9.69e-05	0.000376	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—EGFR—ovarian cancer	9.69e-05	0.000376	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	9.35e-05	0.000363	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.2e-05	0.000357	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—KRAS—ovarian cancer	9.16e-05	0.000355	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—YAP1—ovarian cancer	8.68e-05	0.000337	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—FASN—ovarian cancer	8.62e-05	0.000334	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—YAP1—ovarian cancer	8.61e-05	0.000334	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.52e-05	0.00033	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—SLC5A5—ovarian cancer	8.48e-05	0.000329	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—PIK3CA—ovarian cancer	8.41e-05	0.000326	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—SLC2A1—ovarian cancer	8.19e-05	0.000318	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.02e-05	0.000311	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CYP1B1—ovarian cancer	7.85e-05	0.000304	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—HRAS—ovarian cancer	7.78e-05	0.000302	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.49e-05	0.00029	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—IL6—ovarian cancer	7.45e-05	0.000289	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—FASN—ovarian cancer	7.08e-05	0.000274	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PIK3CA—ovarian cancer	7.04e-05	0.000273	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—FASN—ovarian cancer	7.02e-05	0.000272	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	6.96e-05	0.00027	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	6.96e-05	0.00027	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.93e-05	0.000269	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—SLC5A5—ovarian cancer	6.9e-05	0.000268	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—AKT1—ovarian cancer	6.87e-05	0.000266	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	6.72e-05	0.000261	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—SLC2A1—ovarian cancer	6.67e-05	0.000258	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.53e-05	0.000253	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—ABCB1—ovarian cancer	6.47e-05	0.000251	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	6.45e-05	0.00025	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CYP1B1—ovarian cancer	6.39e-05	0.000248	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—TYMS—ovarian cancer	6.35e-05	0.000246	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—AKT1—ovarian cancer	5.75e-05	0.000223	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	5.72e-05	0.000222	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	5.67e-05	0.00022	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.64e-05	0.000219	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—ABCB1—ovarian cancer	5.31e-05	0.000206	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—ABCB1—ovarian cancer	5.26e-05	0.000204	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—TYMS—ovarian cancer	5.21e-05	0.000202	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—TYMS—ovarian cancer	5.17e-05	0.0002	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CAV1—ovarian cancer	5.12e-05	0.000198	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.89e-05	0.00019	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PIK3CG—ovarian cancer	4.66e-05	0.000181	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CAV1—ovarian cancer	4.2e-05	0.000163	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CAV1—ovarian cancer	4.16e-05	0.000161	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PIK3CD—ovarian cancer	4.1e-05	0.000159	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.98e-05	0.000154	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	3.83e-05	0.000148	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	3.79e-05	0.000147	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PIK3CB—ovarian cancer	3.57e-05	0.000138	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	3.36e-05	0.00013	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	3.33e-05	0.000129	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PTEN—ovarian cancer	3.09e-05	0.00012	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.93e-05	0.000114	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	2.91e-05	0.000113	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PTEN—ovarian cancer	2.53e-05	9.82e-05	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PTEN—ovarian cancer	2.51e-05	9.74e-05	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PIK3CA—ovarian cancer	2.18e-05	8.44e-05	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.79e-05	6.93e-05	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—AKT1—ovarian cancer	1.78e-05	6.9e-05	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.77e-05	6.87e-05	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—AKT1—ovarian cancer	1.46e-05	5.66e-05	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—AKT1—ovarian cancer	1.45e-05	5.61e-05	CbGpPWpGaD
